Literature DB >> 20221697

Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1.

Chie Nishioka1, Takayuki Ikezoe, Jing Yang, Akihito Yokoyama.   

Abstract

We previously showed that the MEK inhibitor AZD6244 induced apoptosis in acute myelogenous leukemia (AML) HL60 cells. However, the mechanisms of AZD6244 to induce apoptosis remain to be fully elucidated. This study found that exposure of HL60 cells to AZD6244 down-regulated the levels of phosphor (p)-4E-binding protein 1 (4E-BP1), a substrate of mammalian target of rapamycin complex 1 (mTORC1), and anti-apoptotic protein Mcl-1. On the other hand, exposure of EOL-1 and MOLM13 cells to AZD6244 failed to induce apoptosis and levels of p-4E-BP1 and Mcl-1 were not down-regulated in these cells. These observations prompted us to hypothesize that down-regulation od 4E-BP1 and Mcl-1 might play an important role in AZD6244-mediated apoptosis. As expected, down-regulation of 4E-BP1 by an siRNA sensitized EOL-1 cells to AZD6244-mediated apoptosis in parallel with down-regulation of Mcl-1. Moreover, we found that blockade of mTORC1 by RAD001 synergistically enhanced the action of AZD6244 in leukemia cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20221697     DOI: 10.1007/s10495-010-0483-y

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  10 in total

1.  The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.

Authors:  Savita Bhalla; Andrew M Evens; Bojie Dai; Sheila Prachand; Leo I Gordon; Ronald B Gartenhaus
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

2.  mTORC1 is essential for leukemia propagation but not stem cell self-renewal.

Authors:  Takayuki Hoshii; Yuko Tadokoro; Kazuhito Naka; Takako Ooshio; Teruyuki Muraguchi; Naoyuki Sugiyama; Tomoyoshi Soga; Kimi Araki; Ken-Ichi Yamamura; Atsushi Hirao
Journal:  J Clin Invest       Date:  2012-05-24       Impact factor: 14.808

3.  The pathogen recognition receptor NOD2 regulates human FOXP3+ T cell survival.

Authors:  Meher K Rahman; Emilie H Midtling; Phyllis A Svingen; Yuning Xiong; Michael P Bell; Jeanne Tung; Tom Smyrk; Larry J Egan; William A Faubion
Journal:  J Immunol       Date:  2010-05-07       Impact factor: 5.422

4.  Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.

Authors:  David L Hermanson; Sonia G Das; Yunfang Li; Chengguo Xing
Journal:  Mol Pharmacol       Date:  2013-05-21       Impact factor: 4.436

Review 5.  Enhancing venetoclax activity in hematological malignancies.

Authors:  Toshihisa Satta; Steven Grant
Journal:  Expert Opin Investig Drugs       Date:  2020-07-16       Impact factor: 6.206

6.  The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo.

Authors:  Yun Zou; Jianfeng Wang; Xuejiao Leng; Jiwei Huang; Wei Xue; Jin Zhang; Yiran Huang
Journal:  Oncotarget       Date:  2017-03-28

7.  Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells.

Authors:  Ewa Jasek-Gajda; Halina Jurkowska; Małgorzata Jasińska; Jan A Litwin; Grzegorz J Lis
Journal:  Apoptosis       Date:  2019-12       Impact factor: 4.677

8.  Gan-Lu-Yin Inhibits Proliferation and Migration of Murine WEHI-3 Leukemia Cells and Tumor Growth in BALB/C Allograft Tumor Model.

Authors:  Fon-Chang Liu; Chun-Hsu Pan; Ming-Tsung Lai; Shu-Jen Chang; Jing-Gung Chung; Chieh-Hsi Wu
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-17       Impact factor: 2.629

9.  Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.

Authors:  Yanan Gao; Juan Gao; Minghao Li; Yawei Zheng; Yajie Wang; Hongyan Zhang; Weili Wang; Yajing Chu; Xiaomin Wang; Mingjiang Xu; Tao Cheng; Zhenyu Ju; Weiping Yuan
Journal:  J Hematol Oncol       Date:  2016-04-12       Impact factor: 17.388

10.  Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells.

Authors:  Yizhou Zeng; Xiaofang Tian; Quan Wang; Weiyang He; Jing Fan; Xin Gou
Journal:  Drug Des Devel Ther       Date:  2018-04-19       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.